DDInter1729 DDInter1335
Sulindac is a nonsteroidal anti-inflammatory drug (NSAID) of the arylalkanoic acid class that is marketed by Merck under the brand name Clinoril. Like other NSAIDs, it may be used in the treatment of acute or chronic inflammatory conditions. Sulindac is a prodrug, derived from sulfinylindene, that is converted _in vivo_ to an active sulfide compound by liver enzymes. There is evidence from some studies that sulindac may be associated with fewer gastrointestinal side effects than other NSAIDs, except for the cyclooxygenase-2 (COX-2) inhibitor drug class. This may be due to the sulfide metabolite undergoing enterohepatic circulation thus maintaining constant blood levels of the compound without inducing gastrointestinal effects, where the drug is excreted in the bile and then reabsorbed from the intestines. While its full mechanism of action is not fully understood, sulindac
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is regulated by {v} (Gene) HIST1H2BK
HIST1H2BK {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) CYP1A1
CYP1A1 {u} (Gene) regulates {v} (Gene) COG4
COG4 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) PTGDR2
PTGDR2 {u} (Gene) is bound by {v} (Compound) Indomethacin
Indomethacin {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) AKR1B1
AKR1B1 {u} (Gene) interacts with {v} (Gene) IKBKE
IKBKE {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) PTGS1
PTGS1 {u} (Gene) interacts with {v} (Gene) NUCB1
NUCB1 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) PPARD
PPARD {u} (Gene) interacts with {v} (Gene) GADD45B
GADD45B {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac {u} (Compound) binds {v} (Gene) MAPK3
MAPK3 {u} (Gene) interacts with {v} (Gene) RPS6KA2
RPS6KA2 {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Sulindac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is regulated by HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Sulindac (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) regulates COG4 (Gene) and COG4 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Sulindac (Compound) binds PTGDR2 (Gene) and PTGDR2 (Gene) is bound by Indomethacin (Compound) and Indomethacin may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Sulindac (Compound) binds AKR1B1 (Gene) and AKR1B1 (Gene) interacts with IKBKE (Gene) and IKBKE (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Sulindac (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Sulindac (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) interacts with NUCB1 (Gene) and NUCB1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Sulindac (Compound) binds PPARD (Gene) and PPARD (Gene) interacts with GADD45B (Gene) and GADD45B (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Sulindac (Compound) binds MAPK3 (Gene) and MAPK3 (Gene) interacts with RPS6KA2 (Gene) and RPS6KA2 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)